VNUS Medical Technologies to Report Second-Quarter 2008 Results and Webcast Teleconference ...(NUSClosure catheters. For more informati...),Health
Navigation Links
VNUS Medical Technologies to Report Second-Quarter 2008 Results and Webcast Teleconference on July 29
Date:7/14/2008
NUS Closure catheters. For more information, please visit the corporate website at http://www.vnus.com.
'/>"/>
| SOURCE VNUS Medical Technologies, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
Breaking Medicine News(10 mins):Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 2Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 3Health News:VHI Releases Annual Industry Report - Highlights Hospital, Nursing Facility Efficiency 2Health News:UPMC Health Plan Offers Brain Fitness Software to Improve Health 2Health News:UPMC Health Plan Offers Brain Fitness Software to Improve Health 3Health News:MassMutual Recognized as One of America's Healthiest Companies 2Health News:MassMutual Recognized as One of America's Healthiest Companies 3Health News:New research identifies modifiable risk factors for heart disease 2Health News:New research identifies modifiable risk factors for heart disease 3Health News:New research identifies modifiable risk factors for heart disease 4Health News:New research identifies modifiable risk factors for heart disease 5Health News:New research identifies modifiable risk factors for heart disease 6
[0] Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange[0] VHI Releases Annual Industry Report - Highlights Hospital, Nursing Facility Efficiency[0] UPMC Health Plan Offers Brain Fitness Software to Improve Health[0] MassMutual Recognized as One of America's Healthiest Companies[0] New research identifies modifiable risk factors for heart disease
Other Medicine News:Health News:AB 1019: It's Time for Big Alcohol to Pay Up 2Health News:Vince Papale and Eagles Fly for Leukemia Tee Up for a Cure at May 4, 2009 Celebrity Golf Classic and Auction 2Health News:Surgical education programs have demand for physician assistants and nurse practitioners 2Health News:AST Leaders Fly to Capitol Hill to Garner and Secure Support for Transplantation Initiatives 2Health News:Colgate-Palmolive Partners With Share Our Strength To Host Online Contest To Combat Childhood Hunger 2Health News:Colgate-Palmolive Partners With Share Our Strength To Host Online Contest To Combat Childhood Hunger 3Health News:Photos: Questions About Autism? The Brooklyn Autism Center Academy Can Help. 2Health News:Photos: Questions About Autism? The Brooklyn Autism Center Academy Can Help. 3
AB 1019: It's Time for Big Alcohol to Pay UpVince Papale and Eagles Fly for Leukemia Tee Up for a Cure at May 4, 2009 Celebrity Golf Classic and AuctionSurgical education programs have demand for physician assistants and nurse practitionersAST Leaders Fly to Capitol Hill to Garner and Secure Support for Transplantation InitiativesColgate-Palmolive Partners With Share Our Strength To Host Online Contest To Combat Childhood HungerPhotos: Questions About Autism? The Brooklyn Autism Center Academy Can Help.
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Mesa Labs Increases Quarterly Dividend 61255 1Neogen to Ring NASDAQs Closing Bell 14815 1Neogen to Ring NASDAQs Closing Bell 14815 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 1Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 3
[0] Boston Scientific Announces Pricing of $2 Billion of Senior Notes[0] Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy[0] Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |